Compare ALTG & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALTG | FHTX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 111.1M |
| IPO Year | 2019 | 2020 |
| Metric | ALTG | FHTX |
|---|---|---|
| Price | $6.09 | $2.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $9.82 | $4.17 |
| AVG Volume (30 Days) | 201.3K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,835,900,000.00 | $30,909,000.00 |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $3.28 | $15.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $4.16 | $1.79 |
| 52 Week High | $8.69 | $7.61 |
| Indicator | ALTG | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.26 | 17.24 |
| Support Level | $5.75 | $1.79 |
| Resistance Level | $6.45 | $5.85 |
| Average True Range (ATR) | 0.32 | 0.23 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 23.12 | 4.14 |
Alta Equipment Group Inc is an integrated equipment dealership platform in the U.S. Its segments are Material Handling, Construction Equipment, and Master Distribution. The Material Handling segment is engaged in operations related to the sale, service, and rental of lift trucks in Michigan, Illinois, Indiana, New York, Virginia, and throughout the New England states whereas, the Construction Equipment segment is principally engaged in operations related to the sale, service, and rental of construction equipment in Michigan, Indiana, Illinois, Ohio, Pennsylvania, New York, Florida and throughout the New England States, and The Master Distribution segment is engaged in environmental processing equipment distribution with sub dealers throughout the United States and Canada.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.